Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Alza’s Ionsys To Launch In 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

The fentanyl treatment’s availability waits on completion of a risk management plan despite FDA approval.

You may also be interested in...



J&J Advances Pipeline With Yondelis, Carisbamate Filings

Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures

J&J Advances Pipeline With Yondelis, Carisbamate Filings

Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures

J&J Advances Pipeline With Yondelis, Carisbamate Filings

Company is on track to achieve goal of filing seven to 10 new products from the beginning of 2008 through end of 2010, CEO Weldon says.

Related Content

Topics

UsernamePublicRestriction

Register

PS064209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel